Save on casirivimab with the RxLess Assurance Plan.
What is casirivimab?
AUTHORIZED USE 1.1 TREATMENT REGEN-COV (casirivimab and imdevimab) co-formulated product and REGEN-COV (casirivimab and imdevimab) supplied as individual vials to be administered together, is authorized for use under an EUA for the treatment of mild to moderate COVID-19 in adult and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 vi...ral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Limitations of Authorized Use REGEN-COV is not authorized for treatment of mild to moderate COVID-19 in geographic regions where infection is likely to have been caused by a non-susceptible SARS-CoV-2 variant based on available information such as variant susceptibility to this drug and regional variant frequency. - FDA's determination and any updates will be available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs. REGEN-COV (casirivimab and imdevimab) is not authorized for use in patients: - who are hospitalized due to COVID-19, OR - who require oxygen therapy due to COVID-19, OR - who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity. Monoclonal antibodies, such as REGEN-COV, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation [see Warnings and Precautions (5.2) ] . 1.2 POST-EXPOSURE PROPHYLAXIS REGEN-COV (casirivimab and imdevimab) co-formulated product and REGEN-COV (casirivimab and imdevimab) supplied as individual vials to be administered together, is authorized for use under an EUA for the post-exposure prophylaxis of COVID-19 in adult and pediatric individuals (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death, and are: not fully vaccinated Individuals are considered to be fully vaccinated 2 weeks after their second vaccine dose in a 2-dose series (such as the Pfizer or Moderna vaccines), or 2 weeks after a single-dose vaccine (such as Johnson & Johnson's Janssen vaccine). See this website for more details: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html#vaccinated or who are not expected to mount an adequate immune response to complete SARS-CoV-2 vaccination (for example, individuals with immunocompromising conditions including those taking immunosuppressive medications See this website for more details: https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/fully-vaccinated-people.html ) and - have been exposed to an individual infected with SARS-CoV-2 consistent with close contact criteria per Centers for Disease Control and Prevention (CDC) Close contact with an infected individual is defined as: being within 6 feet for a total of 15 minutes or more, providing care at home to someone who is sick, having direct physical contact with the person (hugging or kissing, for example), sharing eating or drinking utensils, or being exposed to respiratory droplets from an infected person (sneezing or coughing, for example). See this website for additional details: https://www.cdc.gov/coronavirus/2019-ncov/if-you-are-sick/quarantine.html or - who are at high risk of exposure to an individual infected with SARS-CoV-2 because of occurrence of SARS-CoV-2 infection in other individuals in the same institutional setting (for example, nursing homes, prisons). Limitations of Authorized Use REGEN-COV is not authorized for post-exposure prophylaxis of COVID-19 in geographic regions where exposure is likely to have been to a non-susceptible SARS-CoV-2 variant, based on available information including variant susceptibility to this drug and regional variant frequency. - FDA's determination and any updates will be available at: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs. Post-exposure prophylaxis with REGEN-COV (casirivimab and imdevimab) is not a substitute for vaccination against COVID-19. REGEN-COV (casirivimab and imdevimab) is not authorized for pre-exposure prophylaxis for prevention of COVID-19.
Read More
Once you download the RxLess mobile app, you become a member of the RxLess Assurance plan and will pay the lowest possible price for your casirivimab medication. Review the discount offers and pharmacy prices below. Then, select the offer you want and present it to the pharmacist when you fill your prescription to get that price. That's it! There is nothing more to do or pay. Learn more about how the RxLess Assurance Plan works, or visit our FAQ page if you have questions. If you experience ANY issues at the pharmacy, please call us at 1-844-479-5377 for prompt assistance.
Generic: Brand:
Currently No Prices Available for casirivimab. Use this free discount card to save at your pharmacy.
More ways to save on casirivimab
Fill a 90-Day Supply to Save
In some cases, filling your prescription for a 90-day supply will give you a lower total cost compared to filling the same prescription multiple times for smaller amounts. Even if the drug and the dosage are the same, you will need a brand new prescription from your doctor to switch to 90-day fills.
Your pharmacy cannot transfer a prescription for a 30-day supply into one with a 90-day supply. Also, some insurance plans may require that you use a mail order pharmacy for prescriptions greater than a 30-day supply.
Patient Assistance Programs
Many programs are available from government organizations, non-profits, and drug manufacturers to assist with the costs of medications. It’s free to sign up for these programs if you meet their requirements for eligibility. The enrollment options are different for each program, but they can usually be completed on- line, over the phone, or with the help of your doctor’s office.
Please note, patient assistance programs cannot be used in conjunction with these RxLess offers. Many times however, the offers listed on RxLess will be less expensive than manufacturer coupons, copay cards, or patient assistance programs – so make sure you compare all options before making a purchase.
Research Lower Cost Alternatives
There may be other prescriptions that work equally well at treating a condition, but that are available at different prices. Ask your doctor if there are any lower cost alternative drugs that - and if switching to a different drug could affect your treatment. To get started, check the section below for other drugs related to casirivimab.